Texas Files Lawsuit Against Tylenol Manufacturers
In a major legal development, Texas Attorney General Ken Paxton has filed a lawsuit against Johnson & Johnson and Kenvue, alleging that the companies deceptively marketed Tylenol to pregnant women while concealing possible links between prenatal exposure and developmental disorders such as autism and ADHD.
The case, filed on October 28, 2025, marks a significant challenge for both pharmaceutical giants. It alleges that they failed to properly inform consumers about the potential risks associated with acetaminophen, the active ingredient in Tylenol, when taken during pregnancy.
Allegations of Deceptive Marketing
According to the complaint, the companies promoted Tylenol as a completely safe and reliable medication for expectant mothers, despite growing evidence that frequent use during pregnancy could be associated with certain neurodevelopmental outcomes.
The Texas Attorney General’s office claims that Johnson & Johnson used its 2023 corporate restructuring to transfer liabilities related to over-the-counter medicines to Kenvue, attempting to protect itself from future lawsuits.
Attorney General Ken Paxton said in a statement,
“Texas families deserve honesty and transparency. Instead, these corporations misled the public for years, putting profit above health. Pregnant women have the right to know the risks before making decisions about their care.”
The lawsuit seeks civil penalties, restitution, and stricter warning requirements on acetaminophen products marketed to pregnant women.
Both Johnson & Johnson and Kenvue have strongly denied the accusations.
A spokesperson for Kenvue said,
“The claims are baseless. Acetaminophen is widely recognized by health authorities around the world as a safe pain reliever during pregnancy when used as directed.”
Johnson & Johnson echoed this position, noting that Tylenol has been a trusted brand for over 70 years and remains supported by clinical research and regulatory reviews.
“We are confident the science supports the safety of our products,” the company said. “We will vigorously defend against these allegations.”
Scientific Evidence and Expert Opinion
The lawsuit cites several observational studies that suggest a potential association between frequent use of acetaminophen during pregnancy and a higher risk of autism or ADHD in children. However, scientists emphasize that these studies do not prove a causal relationship.
The U.S. Food and Drug Administration (FDA) reviewed similar research and concluded that the data is inconclusive, stating that no definitive link has been established. The agency has not required any labeling changes but continues to monitor the issue.
Likewise, the American College of Obstetricians and Gynecologists (ACOG) maintains that acetaminophen remains a safe and necessary medication for treating fever or pain during pregnancy when used responsibly. ACOG warns that untreated fever can itself pose significant risks to the fetus.
Public Health Reactions
The lawsuit has sparked mixed reactions among health professionals and the public. Some experts argue that legal actions like this may create unnecessary fear, while others see it as an opportunity to improve transparency and patient education.
Dr. Melissa Rayburn, an obstetrician at the University of Texas Health Center, noted:
“Occasional use of acetaminophen remains appropriate for pregnant women. The key is moderation and medical supervision. The danger often lies in long-term, high-dose use without consulting a doctor.”
Health authorities continue to recommend that pregnant individuals use the lowest effective dose for the shortest necessary duration, and always seek professional medical advice.
Legal and Political Implications
If Texas succeeds, the case could have major financial and regulatory consequences for Johnson & Johnson and Kenvue, potentially encouraging other states to pursue similar actions.
Legal analysts note that the lawsuit aligns with Attorney General Paxton’s broader campaign to hold large corporations accountable for misleading consumers. The case also feeds into the growing public discourse around corporate transparency and medical ethics.
Meanwhile, the companies face pressure not just in the courtroom but also in the court of public opinion. Investors and healthcare professionals are watching closely as the lawsuit progresses through the legal system.
What’s Next for Tylenol
Despite the lawsuit, Tylenol remains available in stores, and health experts stress there is no immediate reason for consumers to stop using it as directed. However, this case is expected to reignite conversations around the safety of common over-the-counter medications during pregnancy.
The trial process may take years, but its outcome could shape the future of drug labeling and consumer trust in pharmaceutical brands.
Conclusion
The Texas lawsuit against Tylenol makers Johnson & Johnson and Kenvue underscores the tension between corporate accountability, scientific uncertainty, and consumer protection. While the courts will determine whether the companies misled the public, the case highlights an essential message: even widely trusted medications require continued scrutiny and transparent communication about potential risks.
For now, experts urge calm and moderation — reminding consumers that informed medical guidance remains the safest path forward.